TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

VITAMIN K1

PHYTONADIONE
Immunology Approved 1983-07-25
1
Indication
--
Phase 3 Trials
42
Years on Market

Details

Status
Prescription
First Approved
1983-07-25
Routes
INJECTION
Dosage Forms
INJECTABLE

Companies

Active Ingredient: PHYTONADIONE

VITAMIN K1 Approval History

Loading approval history...

What VITAMIN K1 Treats

10 indications

VITAMIN K1 is approved for 10 conditions since its original approval in 1983. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Coagulation Disorder
  • Hypoprothrombinemia
  • Obstructive Jaundice
  • Biliary Fistula
  • Sprue
  • Ulcerative Colitis
  • Celiac Disease
  • Cystic Fibrosis
Source: FDA Label

VITAMIN K1 Boxed Warning

HYPERSENSITIVITY REACTIONS WITH INTRAVENOUS AND INTRAMUSCULAR USE Fatal hypersensitivity reactions, including anaphylaxis, have occurred during and immediately after intravenous and intramuscular injection of Vitamin K 1 Injection. Reactions have occurred despite dilution to avoid rapid intravenous infusion and upon first dose. Avoid the intravenous and intramuscular routes of administration unless the subcutaneous route is not feasible and the serious risk is justified [see Warnings and Precaut...

Drugs Similar to VITAMIN K1

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

PHYTONADIONE
PHYTONADIONE
7 shared
AMNEAL PHARMS CO
Shared indications:
Coagulation DisorderObstructive JaundiceBiliary Fistula +4 more
ABRILADA
ADALIMUMAB-AFZB
1 shared
Pfizer
Shared indications:
Ulcerative Colitis
ALYFTREK
DEUTIVACAFTOR
1 shared
Vertex Pharmaceuticals
Shared indications:
Cystic Fibrosis
AMJEVITA
ADALIMUMAB-ATTO
1 shared
Amgen
Shared indications:
Ulcerative Colitis
APRISO
MESALAMINE
1 shared
SALIX
Shared indications:
Ulcerative Colitis
AVSOLA
INFLIXIMAB-AXXQ
1 shared
Amgen
Shared indications:
Ulcerative Colitis
AZULFIDINE EN-TABS
SULFASALAZINE
1 shared
Pfizer
Shared indications:
Ulcerative Colitis
BALSALAZIDE DISODIUM
BALSALAZIDE DISODIUM
1 shared
ZYDUS LIFESCIENCES
Shared indications:
Ulcerative Colitis
BETHKIS
TOBRAMYCIN
1 shared
CHIESI
Shared indications:
Cystic Fibrosis
CAYSTON
AZTREONAM
1 shared
Gilead Sciences
Shared indications:
Cystic Fibrosis
COLAZAL
BALSALAZIDE DISODIUM
1 shared
VALEANT PHARMS INTL
Shared indications:
Ulcerative Colitis
CORTENEMA
HYDROCORTISONE
1 shared
ANI PHARMS
Shared indications:
Ulcerative Colitis
CYLTEZO
ADALIMUMAB-ADBM
1 shared
Boehringer Ingelheim
Shared indications:
Ulcerative Colitis
DIPENTUM
OLSALAZINE SODIUM
1 shared
Viatris
Shared indications:
Ulcerative Colitis
ENTYVIO
VEDOLIZUMAB
1 shared
Takeda
Shared indications:
Ulcerative Colitis
HADLIMA
ADALIMUMAB-BWWD
1 shared
SAMSUNG BIOEPIS CO LTD
Shared indications:
Ulcerative Colitis
HULIO
ADALIMUMAB-FKJP
1 shared
Viatris
Shared indications:
Ulcerative Colitis
HUMIRA
ADALIMUMAB
1 shared
AbbVie
Shared indications:
Ulcerative Colitis
HYRIMOZ
ADALIMUMAB-ADAZ
1 shared
Novartis
Shared indications:
Ulcerative Colitis
IDACIO
ADALIMUMAB-AACF
1 shared
Fresenius Kabi
Shared indications:
Ulcerative Colitis
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

VITAMIN K1 FDA Label Details

Pro

Indications & Usage

Vitamin K 1 Injection is a vitamin K replacement indicated for the treatment of the following coagulation disorders which are due to faulty formation of factors II, VII, IX and X when caused by vitamin K deficiency or interference with vitamin K activity. • Anticoagulant-induced hypoprothrombinemia deficiency caused by coumarin or indanedione derivatives. • Hypoprothrombinemia due to antibacterial therapy. • Hypoprothrombinemia secondary to factors limiting absorption or synthesis of vitamin K, e.g., obstructive jaundice, biliary fistula, sprue, ulcerative colitis, celiac disease, intestinal r...

⚠️ BOXED WARNING

WARNING: HYPERSENSITIVITY REACTIONS WITH INTRAVENOUS AND INTRAMUSCULAR USE Fatal hypersensitivity reactions, including anaphylaxis, have occurred during and immediately after intravenous and intramuscular injection of Vitamin K 1 Injection. Reactions have occurred despite dilution to avoid rapid int...

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.